. "CORT-125134"@en . "CN1C=CSN2CCC3=CC4=CC=NN4C6=CC=CF"@en . . . "1"^^ . "27"^^ . . . . "73051463"^^ . . . "56104974"^^ . "2158753C7E" . "[-1--6-sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-pyridin-2-yl]methanone"@en . "2158753"^^ . . "57617720"^^ . . "WANIDIGFXJFFEL-SANMLTNESA-N"@en . . "73051463" . . . . "D11336"@en . . . . "1496510"^^ . . . . . . "1496510-51-0" . "4"^^ . "3"^^ . . . "22"^^ . "6"^^ . "Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is also under development for the treatment of solid tumors and alcoholism. The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor. As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown."@en . . . "3454"^^ . . . . . . "Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is also under development for the treatment of solid tumors and alcoholism. The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor. As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown."@en . . . . . . . . . . . . "1084240921"^^ . . "Relacorilant"@en . . . . "D11336" . . "1"^^ . . .